SUBSEQUENT EVENTS |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Subsequent Events [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SUBSEQUENT EVENTS | SUBSEQUENT EVENTS These financial statements include a discussion of material events that have occurred subsequent to September 30, 2026 through the issuance of these financial statements. Events subsequent to that date have not been considered in these financial statements. Capital Raise Activity Since October 1, 2026, the Company issued the following shares, including shares issued under the Company's distribution reinvestment plan:
Distributions Since October 1, 2026, the Company declared the following distributions per share:
Entry into Amendment No. 1 to the Advisory Agreement On November 9, 2026, the Company and the Adviser entered into Amendment No. 1 (the “Amendment”) to the Advisory Agreement to extend the period during which the Adviser is required to advance Organization and Offering Expenses (as defined in the Advisory Agreement), thereby deferring the commencement of the Company’s reimbursement of those expenses. As amended, this period continues through the later of (i) the date on which the Company’s aggregate NAV is at least $200.0 million and (ii) December 1, 2027, the second anniversary of the date on which the Company first calculated NAV. The Company does not currently anticipate additional advances of such expenses during the extension period. Previously advanced expenses will remain reimbursable in 60 equal monthly installments following the end of the advancement period. All other terms of the Advisory Agreement remain unchanged.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||